Financial intelligence for Asia's healthcare markets
 
 
Remember me:

EXCLUSIVE: Qualitas to push button on IPO next week

Malaysian-based primary healthcare provider Qualitas Medical Group is due to push the button on its S$150 million (US$114 million) IPO in Singapore next week. It will be the first mainboard healthcare listing since IHH Healthcare floated in Kuala Lumpur and Singapore in July 2012.

Backed by Singaporean private equity firm Southern Capital Group, global coordinators are CIMB and Credit Suisse with DBS and Daiwa as bookrunners.

Investors are expected to jump at the deal which will see around 25% of the group floated. Although no cornerstone investors have been signed up, it is significant that Southern Capital is not selling down any of its 78% stake, which post IPO will be around 55%.

A successful IPO from Qualitas will be a shot in the arm for the SGX. In recent months a number of healthcare companies have looked at other exchanges. In late February primary healthcare services provider Republic Healthcare said that it planned to IPO on Hong Kong’s junior GEM board while HKE Holdings, a Singapore-based contractor specialising in the medical and healthcare sectors, said it was looking at the same board in September last year.

Not that the SGX is as subdued as some critics would have you believe. Healthcare services group Clearbridge Health raised S$24.6 million in its IPO on the Catalist, SGX’s junior board, in late December. It sold 88 million shares, or 18.3% of its enlarged share capital, at S$0.28 per share. Its shares have performed well and were last seen at S$0.54. In the wings too is Luye Medical Group, the regional healthcare services arm of Luye Life Sciences Group. At the start of March it mandated Bank of America Merrill Lynch, Credit Suisse and UBS for its up-to S$500 million SGX IPO.

But Qualitas is very focused on Singapore and an SGX listing makes sense for the group. It is not raising a massive amount, valuations for healthcare companies in Singapore are healthy and that is where growth for the company is likely to come from. Although the group is looking for acquisitions across the region, a significant proportion of proceeds will be used to buy clinics in Singapore.

Although it is too early to talk about an indicative range, bankers are looking to IHH and Health Management International – both based in Malaysia – as well as Singapore businesses like Q&M Dental and Singapore Medical Group, for comps.

This is Qualitas’ second attempt at a float. Although pricing had been set on the deal and cornerstone investors had been signed up, it pulled an IPO in the autumn of 2015. Chairman and managing director Noorul Ameen Mohamed Ishack said that the decision had been taken thanks to unfavourable market conditions, though those away from the deal said that the water had been muddied as CIMB and Credit Suisse were looking after the IPO while a parallel private sale was also explored by via Rothschild. Investors were said to be confused by mixed messages.

Founded in 1997, Qualitas Medical  operates a network of clinics in Malaysia with medical centres in Singapore, India, and Australia. It was listed on Singapore’s Catalist board in 2008. It was taken private in 2011 for US$36 million.

Bookbuilding is expected to begin next week with a listing planned for mid April.

Posted on: 23/03/2018 UTC+08:00


News

Metro Pacific Hospital Holdings, the healthcare unit of industrial conglomerate Metro Pacific Investments, is finally expected to push the button on its Philippine Stock Exchange IPO next year.
MedAdvisor will form a 50:50 joint venture based in Singapore with Zuellig Pharma to commercialise MedAdvisor’s medication management platform in Asia.
Thermo Fisher Scientific, the world leader in serving science, today opened its first Bioprocess Design Centre in Shanghai, China. The new centre is part of a strategy to establish a centre of excellence where Thermo Fisher scientists can connect and collaborate with biologic developers to design optimal bioprocessing solutions.
Mitsui & Co will acquire an additional 16% of the shares of one of Asia’s largest private hospital groups, IHH Healthcare, from Malaysia’s Khazanah Nasional.
Mach7 Technologies, a company specialising in innovative data management solutions for healthcare providers, has raised A$3 million (US$2.2 million) via a private placement.
Pacific Edge is to raise NZ$12 million (US$8.2 million) in a share placement and via a share purchase plan.
We Doctor Holdings, China's leading technology-enabled medical and healthcare solutions platform, joined hands today in Guangzhou with the Guangdong Women and Children's Hospital and Health Institute to launch China's first provincial-level internet hospital for women and children.
Singapore-based medtech startup Ark has raised US$40 million in Series A funding round led by Venturecraft shareholders and joined by Gaorong Capital – formerly known as Banyan Capital. It is one of the largest Series A rounds closed by a southeast Asian firm.



Analysis

French-based international ophthalmic optics company Essilor has signed Letters of Intent with the Royal Government of Bhutan and the Central Monastic Body to strengthen the country’s vision care infrastructure.
April Chang, country manager at Cigna Singapore, argues that wellness programmes at work can lead to reduced absenteeism, higher productivity and increased morale among employees.
Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services.
Imagine a world in which you can consult with your doctor via video. She asks for a blood sample, which can be collected and analysed from a device in your home. After that is diagnosed, the prescription is automatically sent to the pharmacy and Uber then picks it up. The time from diagnosis to drugs at your home is only 60 minutes.
The digitisation of health data through blockchain technology is a groundbreaking solution that will empower patients and provide them with better access to healthcare.
For too many companies, a stock market flotation is the be all and end all. Chief executives have spent months on roadshows, locked up with bankers and lawyers. Understandably they think that they can now rest on their laurels.
Today is the launch of Asia Pacific’s first Life Sciences Centre of Excellence. It is part of global management consulting firm LEK Consulting’s Healthcare Insights Centre and aims to drive thought leadership and innovation to elevate the life sciences ecosystem in Singapore and the region.
Dementia remains one of the biggest chronic medical issues to face families. A determination to treat the illness is a challenge that Charles Stacey, president and CEO of Singapore-based Cerecin, has grasped with both hands.
my images

Podcasts

HealthInvestor Asia twitter feed